| News

Hemex attracts Swiss investors

11.02.2021

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The biotech incubator will use the funds to accelerate its global expansion.

Hemex, a Basel Area-based venture capitalist and incubator for biotech startups, has reported raising “a substantial amount” in an oversubscribed Series C financing round. According to a press release, the capital contribution was raised exclusively from a group of Swiss private investors.

Now, Hemex plans to use this money to hire “world-class talent” and accelerate its global expansion. The company wants to “invest in carefully selected startups” and deliver on its promise of “changing the future of healthcare”.

“We anticipate another year of strong growth for healthcare, both domestically and on a global level,” said Hemex CEO Pascal Winnen in the press release. “This vote of confidence for our business model from a group of successful entrepreneurs confirms that Hemex is on the right track for substantial future success.”

Hemex’s partners include the investment and innovation promotion agency Basel Area Business & Innovation and its DayOne Accelerator. Its portfolio includes Opterion Health AG, which announced at the end of January that it would be moving from the canton of Obwalden to the co-working space The 5th Floor in Muttenz. Basel Area Business & Innovation is providing support for the relocation.

In addition, Hemex has invested in Scailyte, a company based at the Novartis Campus of the Switzerland Innovation Park Basel Area. Support has also been provided to Resistell based in Muttenz, which claims to have made the world’s fastest antibiogram, and Basel cancer diagnostics expert Artidis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.